BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — Marcum Micro Cap Conference 2017

18 slides from BioRestorative Therapies's conference presentation, 2017

1. Slide 1: Presentation 2017

   PRESENTATION 2017 OTCQB: BRTX  biorestorative.com

2. Slide 2: Forward Looking Statements

   Forward Looking Statements Statements in this presentation, including the information set forth as to the future financial or operating performance of BioRestorative Therapies, Inc. (the “Company”), that are not current or historical factual statements may constitute “forward looking” information wi

3. Slide 3: Company Overview

   Company Overview BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease and metabolic disorders. MULTIPLE CELL THERAPY PROGRAMS  DISC/SPINE PROGRAM (brtxD

4. Slide 4: Disc Treatment Options

   Disc Treatment Options Current treatment options for the BRTX-100-addressable population range from conservative methods such as medication or physical measures, to more invasive surgical procedures *Discectomy: surgery to remove part of the herniated disc material that presses on a nerve root or th

5. Slide 5: Market (Prevalence Summary)

   Market (Prevalence Summary) Trinity Partners used a multi-pronged approach to determine the prevalence of the BRTX-100-addressable patient population 5

6. Slide 6: Lower Back Pain Disc Therapy Program

   Lower Back Pain Disc Therapy Program Lower Back Pain is the Most Common, the Most Disabling, and the Most Costly Musculoskeletal Problem Treated Protruding / Bulging Disc Spinal Fusion Surgery INTRODUCING A NEW STANDARD OF CARE TO TREAT CHRONIC LUMBAR DISC DISEASE 6

7. Slide 7: Cell-Based Lumbar Disc Therapeutic

   Cell-Based Lumbar Disc Therapeutic Disc Therapy to Treat Chronic Lumbar Disc Disease (Protruding and Bulging Discs)  BRTX-100 - Lead Cell Therapy Candidate Product Formulated from Autologous Hypoxic Cultured Mesenchymal Stem Cells (or MSCs) Collected from the Patient’s Bone Marrow and Co- Administe

8. Slide 8: BRTX-100 Product Benefits

   BRTX-100 Product Benefits Hypoxic Culture Conditions – A Solution for Mesenchymal Stem Cell Based Regenerative Medicine Hypoxic Culture Benefits Increased Cell Proliferation Greater Plasticity Increased Paracrine Effect Increased Cell Survival BRTX-100 - A Safer and More Potent Product BRTX-100 Meso

9. Slide 9: BRTX-100: Production Process - 5 Weeks

   BRTX-100: Production Process - 5 Weeks Collection and Shipment to BRT of Patient’s Bone Marrow and Blood Production of BRTX-100 Thawing and Injection of • Hypoxic BRTX-100 into Culturing of Patient’s Disc MSCs • Biomaterial Carrier Shipment of Formulation and BRTX-100 to Cryopreservation Clinical of

10. Slide 10: Human Clinical Experience

    Human Clinical Experience HUMAN CLINICAL EXPERIENCE SAFETY STUDY 10

11. Slide 11: Disc Morphologic Changes

    Disc Morphologic Changes Therapy May Have a Significant Impact on the Morphology of the Disc  42 yo Male needed epidural steroid Apr 2009-Sag T2 FRFSE FS 4/2009 ET-24, TR-4233, TE-105.2 injections multiple times annually PRE-TREATMENT for radiculopathy  Large central, contained, broad based protru

12. Slide 12: BRTX-100: Clinical Trial Design

    BRTX-100: Clinical Trial Design  Trial Design: A Phase 2 Prospective, Double-Blinded, Placebo Controlled, Randomized Study, n=72  Evaluate Safety and Efficacy of a Single Dose of BRTX-100  15+ Clinical Trial Sites  Primary Efficacy Endpoint – 6 months  Patient Follow Up – 12 months, 24 months 

13. Slide 13: Key Highlights - Value Proposition

    Key Highlights - Value Proposition  Unique Product Engineered to Address the Challenges of the Targeted Application  Autologous Hypoxic-Cultured Cell Product  BRTX-100 is Formulated and Co-Administered with Biomaterial Carrier  Prior Hypoxic-Cultured Cell Therapy Clinical Experience  BioRestora

14. Slide 14: ThermoStem Program (Brown Adipose Stem Cells)

    ThermoStem® Program (Brown Adipose Stem Cells) Potential Treatments for Metabolic Diseases Volume 32, Number 2, February 2014  Pre-clinical allogeneic cell-based therapy to target obesity, diabetes and metabolic The International Journal of Cell Differentiation and Proliferation disorders using bro

15. Slide 15: Preclinical Metabolic Results: Glucose and Body Weight

    Preclinical Metabolic Results Glucose and Body Weight Blood Glucose Levels Body Weight 600 40 35 500 30 Body weight (g) 400 25 Glucose (mg/dl) 20 300 15 200 10 5 100 0 1 2 3 4 5 6 7 8 9 10 11 12 13 0 Control 1 2 3 4 5 6 7 8 9 10 11 12 13 Weeks after transplantation Control BADSC Weeks after transpla

16. Slide 16: Preclinical Metabolic Results: Triglycerides and Cholesterol

    Preclinical Metabolic Results Triglycerides and Cholesterol Levels Triglycerides Level Cholesterol Level Mice fed high chow diet throughout experiment and transplanted with brown adipose derived stem cells (BADSC)/scaffolds and controls 16

17. Slide 17: Brown Fat Delivery Device

    Brown PreclinicalFat Delivery Metabolic Results Device Encapsulation Device/BADSCs HE BF DAPI/Mito/UCP1 A C B DAPI Mito UCP1 Encapsulation Device containing BADSC Immunohistochemical analysis of a cross section that have been differentiated into brown fat. of an encapsulation device containing cells

18. Slide 18: Thank You

    Thank You OTCQB: BRTX  biorestorative.com 18

BioRestorative Therapies — Marcum Micro Cap Conference 2017 on 6ix